Investigating the role of type II arginase in tuberculosis
Type II arginase and tuberculosis pathogenesis
This study is looking at how a specific enzyme called type II arginase (ARG2) influences the immune system's response to tuberculosis (TB), with the hope of finding better ways to treat the disease.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rutgers Biomedical and Health Sciences NIH-funded |
| Lab location | 1 site (Newark, UNITED STATES) |
| Project ID | NIH-10990543 on NIH RePORTER |
What this research studies
This research focuses on understanding how type II arginase (ARG2) affects the immune response to tuberculosis (TB) caused by Mycobacterium tuberculosis. By studying animal models, the researchers aim to uncover the metabolic changes in immune cells during TB infection and how these changes can be harnessed to improve treatment outcomes. The study involves analyzing the dynamics of macrophage responses and the role of ARG2 in regulating inflammation and metabolism. The ultimate goal is to develop new therapies that can enhance the effectiveness of existing TB treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with tuberculosis, particularly those who may be at risk for multi-drug-resistant strains.
Not a fit: Patients with other infectious diseases unrelated to tuberculosis may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that improve treatment outcomes for patients with tuberculosis.
How similar studies have performed: Previous research has shown promise in targeting metabolic pathways in immune responses, suggesting that this approach could yield significant advancements in TB treatment.
Where this research is happening
Newark, UNITED STATES
- Rutgers Biomedical and Health Sciences — Newark, United States (Active)
Researchers
- Principal investigator: Shi, Lanbo — Rutgers Biomedical and Health Sciences
- Study coordinator: Shi, Lanbo
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.